• Michael A Borger, Fedak Paul W M PWM Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada., Elizabeth H Stephens, Thomas G Gleason, Evaldas Girdauskas, John S Ikonomidis, Ali Khoynezhad, Samuel C Siu, Subodh Verma, Michael D Hope, Duke E Cameron, Donald F Hammer, Joseph S Coselli, Marc R Moon, Thoralf M Sundt, Alex J Barker, Michael Markl, Alessandro Della Corte, Hector I Michelena, and John A Elefteriades.
• Leipzig Heart Center, Cardiac Surgery, University of Leipzig, Leipzig, Germany. Electronic address: michael.borger@helios-gesundheit.de.
• J. Thorac. Cardiovasc. Surg. 2018 Aug 1; 156 (2): 473-480.

AbstractBicuspid aortic valve disease is a common congenital cardiac disorder, being present in 1% to 2% of the general population. Associated aortopathy is a common finding in patients with bicuspid aortic valve disease, with thoracic aortic dilation noted in approximately 40% of patients in referral centers. Several previous consensus statements and guidelines have addressed the management of bicuspid aortic valve-associated aortopathy, but none focused entirely on this disease process. The current document is an executive summary of "The American Association for Thoracic Surgery Guidelines on Bicuspid Aortic Valve-Related Aortopathy." All major aspects of bicuspid aortic valve aortopathy, including natural history, phenotypic expression, histology and molecular pathomechanisms, imaging, indications for surgery, surveillance, and follow-up, and recommendations for future research are contained within these guidelines. The current executive summary serves as a condensed version of the guidelines to provide clinicians with a current and comprehensive review of bicuspid aortic valve aortopathy and to guide the daily management of these complex patients.Copyright © 2018 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

28 keywords...

hide…